Clinical trials: Pancreatic Adenocarcinoma Resectable
Pancreatic Cancer, Borderline Resectable Pancreatic Adenocarcinoma
IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer
This study is a Phase II trial evaluating the safety and efficacy of IBI343 in combination with chemotherapy as neoadjuvant therapy for subjects with borderline resectable pancreatic cancer (BRPC).
- Trial name
- NCT07415525
- Testing
- IBI343
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhejiang University
Localized Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma
Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)
Since patients with (borderline) resectable pancreatic cancer have a limited life expectancy, it is important to improve treatment strategies.
- Conditions
- Localized Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma
- Trial name
- PREOPANC-5 (NCT06384560)
- Testing
- Pembrolizumab, Folfirinox, SABR
- Where
- 4 sites in Netherlands
- Volunteers
- 66 people
- Sponsor
- Amsterdam UMC, location VUmc
Borderline Resectable Pancreatic Adenocarcinoma
HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation
This study is a Phase II clinical trial that plans to enroll 40 patients with borderline resectable pancreatic cancer harboring a KRAS G12D mutation, aiming to evaluate the efficacy of HRS-4642 in combination with Nimotuzumab and…
- Trial name
- NCT07240766
- Testing
- HRS-4642+AG+Nimotuzumab
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- Zhejiang University
Resectable Pancreatic Duct Adenocarcinoma
Neo-adjuvant FOLF(IRIN)OX for Resectable Pancreatic Adenocarcinoma
In patients with resectable pancreatic duct adenocarcinoma (PDAC), curative surgery followed by adjuvant chemotherapy is currently the standard of care.
- Trial name
- PANACHE01 (NCT02959879)
- Testing
- FOLFOX neoadjuvant chemotherapy, FOLFIRINOX neoadjuvant chemotherapy, curative surgery for resectable pancreatic duct adenocarcinoma
- Where
- France
- Volunteers
- 153 people
- Sponsor
- University Hospital, Rouen
Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma
Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma
This study will test the effectiveness (anti-tumor activity), safety, and ability to increase the body's immune system to fight pancreatic cancer by combining standard chemotherapy before and after surgery, with study drug PD-1…
- Trial name
- NCT03727880
- Testing
- Pembrolizumab, Defactinib
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Lei Zheng
Pancreatic Ductal Adenocarcinoma (PDAC), Cancer of Pancreas
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
This is a research study to evaluate how the genetic makeup of Pancreatic Ductal Adenocarcinoma (PDAC) can affect the response to FDA-approved chemotherapy treatment, FOLFIRINOX, given before surgery to remove the tumor.
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC), Cancer of Pancreas, Pancreatic Cancer, Adult, Pancreas Adenocarcinoma
- Trial name
- NCT03977233
- Testing
- Oxaliplatin, Leucovorin, Irinotecan Hydrochloride
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Locally Advanced Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma
PULSAR in Systemic Therapy for Pancreatic Cancer
Pancreatic cancer remains one of the malignancies with the lowest survival rates, largely due to late-stage diagnosis and the difficulty of achieving curative resection.
- Conditions
- Locally Advanced Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma, Oligometastatic Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT07269626
- Testing
- Personalized Ultrafractionated Adaptive Radiotherapy
- Where
- South Korea
- Volunteers
- 47 people
- Sponsor
- Samsung Medical Center
Pancreas Adenocarcinoma, Resectable Pancreatic Cancer
Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer
The purpose of this phase 2 research study is to determine whether a combination of chemotherapy drugs plus radiation therapy, given before surgery in resectable pancreactic cancer, can help to increase the chances of surgeons…
- Trial name
- NCT03492671
- Testing
- Gemcitabine 1000 mg, nab-paclitaxel, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Loma Linda University
Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Cancer
Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma
This study is a single-arm, phase I trial, up to 16 participants with resectable PDA. The study will examine the efficacy of the mutant IDH1 inhibitor ivosidenib, in conjunction with standard-of-care mFOLFIRINOX in the…
- Trial name
- NCT05209074
- Testing
- Ivosidenib, mFOLFIRINOX
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Case Comprehensive Cancer Center
Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma
Determining the Link Between Dietary Patterns, Fecal Microbiome and Response to Neoadjuvant Chemotherapy
This study explores the relationship between pre-treatment dietary patterns, fecal microbiome, and response to chemotherapy in patients with pancreatic ductal adenocarcinoma.
- Conditions
- Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma, Stage I Pancreatic Cancer AJCC v8
- Trial name
- NCT06595160
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- Emory University
Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma
A Cohort Study on ctDNA MRD in Neoadjuvant Therapy for Pancreatic Cancer
The goal of this prospective observational study is to learn about the clinical utility of dynamic ctDNA-based Minimal Residual Disease (MRD) monitoring in patients with borderline resectable pancreatic cancer undergoing…
- Trial name
- MRD (NCT07080021)
- Testing
- Standard Reagents, Pancreatic Cancer
- Where
- 2 sites in China
- Volunteers
- 119 people
- Sponsor
- Ruijin Hospital
Pancreatic Adenocarcinoma Resectable
Adjuvant Pancreatic Therapy Guided by MRD
Pancreatic adenocarcinoma (PAAD) is a leading cause of cancer-related deaths worldwide. Although surgical resection can be curative, the 5-year overall survival (OS) rate after resection alone is approximately 20%.
- Trial name
- ADAPT-MRD (NCT06966440)
- Testing
- circulating tumor DNA (ctDNA)-based MRD, adjuvant chemotherapy regimens
- Where
- China
- Volunteers
- 856 people
- Sponsor
- Ruijin Hospital
Pancreatic Cancer Resectable, Pancreatic Ductal Adenocarcinoma
French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)
The overall objective of this GUIDE.MRD consortium is to confirm that ctDNA detected after curative intended treatment for PDAC is a marker of residual disease and for risk-of-recurrence, and applicable in clinical practice.
- Conditions
- Pancreatic Cancer Resectable, Pancreatic Ductal Adenocarcinoma, Minimal Residual Disease, Liquid Biopsy
- Trial name
- NCT06287749
- Testing
- Blood sample/Liquid Biopsy
- Where
- France
- Volunteers
- 37 people
- Sponsor
- University Hospital, Montpellier
Resectable Pancreatic Duct Adenocarcinoma
Prospective Cohort of Patients Treated Using Neoadjuvant Modified FOLFIRINOX 6 Cycles for Potentially Resectable Pancreatic Duct Adenocarcinoma, Candidate for Participation in the PANACHE02 Clinical Trial
The aim of our study is to build up biological, radiological and tissue collections so as to identify, at the time of diagnosis of pancreatic adenocarcinoma, multifactorial factors and/or biomarkers (tissue, plasma, radiomic)…
- Trial name
- PANACHE02-SC (NCT07034703)
- Where
- France
- Volunteers
- 820 people
- Sponsor
- University Hospital, Rouen
Pancreatic Adenocarcinoma Resectable, Neoadjuvant Chemotherapy
Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer
The prognosis of pancreatic cancer is extremely poor. Current guidelines recommend Nab-paclitaxel, Gemcitabine and modified Folfirinox as the first-line chemotherapeutic regimen.
- Trial name
- NCT03750669
- Testing
- AG regimen, mFolfirinox
- Where
- China
- Volunteers
- 324 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Resectable Pancreatic Adenocarcinoma
Perioperative NALIRIFOX (liposomal Irinotecan in Combination with Fluorouracil, Leucovorin, and Oxaliplatin) in Resectable Pancreatic Adenocarcinoma: Randomized Phase II Trial
To explore the safety and activity of NALIRIFOX (liposomal irinotecan in combination with fluorouracil, leucovorin, and oxaliplatin) in the perioperative and adjuvant treatment in resectable pancreatic adeneocarcinoma.
- Trial name
- NCT06816914
- Testing
- NALIRIFOX
- Where
- 9 sites in Taiwan
- Volunteers
- 84 people
- Sponsor
- Taichung Veterans General Hospital
Cancer of Pancreas, Pancreas Adenocarcinoma
Carbon Ions Radiation Therapy for Resectable or Borderline Resectable Pancreas Adenocarcinoma
Relapses free survival will be evaluated as efficacy of carbon ions radiation therapy released before surgery.
- Conditions
- Cancer of Pancreas, Pancreas Adenocarcinoma, Resectable Pancreatic Cancer
- Trial name
- PIOPPO (NCT03822936)
- Testing
- Preoperative chemotherapy, Preoperative radiotherapy
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- CNAO National Center of Oncological Hadrontherapy
Pancreatic Adenocarcinoma, Pancreatic Cancer Non-resectable
mFOLFIRINOX With or Without Stereotactic Body Radiotherapy in Locally Advanced Pancreatic Adenocarcinoma
Modified FOLFIRINOX (mFOLFIRINOX) is the standard of care for patients with locally advanced pancreatic adenocarcinoma. While radiotherapy has been investigated for the management of resectable or locally advanced pancreatic…
- Trial name
- SABER (NCT04986930)
- Testing
- SBRT+mFOLFIRINOX, mFOLFIRINOX
- Where
- South Korea
- Volunteers
- 92 people
- Sponsor
- Asan Medical Center
Colorectal Adenocarcinoma, Gastric Adenocarcinoma
TAS102 in Combination With NAL-IRI in Advanced GI Cancers
This phase I/II trial studies the best dose and how well trifluridine/tipiracil hydrochloride combination agent TAS-102 (TAS-102) and nanoliposomal irinotecan work in treating patients with gastrointestinal cancers that have…
- Conditions
- Colorectal Adenocarcinoma, Gastric Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Non-Resectable Cholangiocarcinoma
- Trial name
- NCT03368963
- Testing
- Nanoliposomal Irinotecan, Trifluridine and Tipiracil Hydrochloride
- Where
- 3 sites in United States
- Volunteers
- 64 people
- Sponsor
- Emory University
Pancreatic Cancer, Resectable Pancreatic Cancer
A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer
This study is being done to evaluate the safety and efficacy of adding NIS793 to standard of care FOLFIRINOX treatment for pancreatic cancer.
- Conditions
- Pancreatic Cancer, Resectable Pancreatic Cancer, Borderline Resectable Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT05546411
- Testing
- mFOLFIRINOX, 5-Fluorouracil (5-FU), Oxaliplatin
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Kimberly Perez, MD